We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AbbVie has signed an exclusive, collaboration and option agreement for the development and commercialisation of Caraway Therapeutics’ small molecule candidates to treat Parkinson’s disease and other related conditions.